Table 1 Characteristics of lung cancer patients by low-dose aspirin use
From: Low-dose aspirin and survival from lung cancer: a population-based cohort study
Characteristics | Total study population | Low-dose aspirin use in year prior to diagnosisa | Low-dose aspirin use after diagnosisb | ||
|---|---|---|---|---|---|
User n (%) | Non-user (%) | Ever n (%) | Never (%) | ||
(n = 14,735) | (n = 13,433) | (n = 3,635) | |||
Year of diagnosis: 1998–2000 | 2,797 (19) | 459 (12) | 1,850 (19) | 175 (15) | 463 (19) |
2001–2003 | 3,708 (25) | 831 (22) | 2,524 (26) | 280 (24) | 603 (24) |
2004–2006 | 4,025 (27) | 1,175 (30) | 2,603 (27) | 322 (28) | 647 (26) |
2007–2009 | 4,205 (29) | 1,404 (36) | 2,587 (27) | 384 (33) | 761 (31) |
Age at diagnosis: < 50 | 492 (3) | 11 (0) | 410 (4) | 10 (1) | 163 (7) |
50–59 | 1,780 (12) | 171 (4) | 1,425 (15) | 97 (8) | 475 (19) |
60–69 | 3,912 (27) | 916 (24) | 2,660 (28) | 362 (31) | 804 (33) |
70–79 | 5,347 (36) | 1,681 (44) | 3,231 (34) | 478 (31) | 775 (31) |
80–89 | 2,898 (20) | 974 (25) | 1,677 (18) | 199 (17) | 242 (10) |
≥90 | 306 (2) | 116 (3) | 161 (2) | 15 (1) | 15 (1) |
Gender: Males | 8,701 (59) | 1,581 (63) | 6,360 (58) | 748 (64) | 1,357 (55) |
Treatment within 6 months of cancer diagnosis | |||||
Surgeryc | 1,324 (12) | 329 (11) | 895 (12) | 305 (34) | 567 (30) |
Chemotherapy | 3,287 (22) | 709 (18) | 2,324 (24) | 309 (27) | 950 (38) |
Radiotherapy | 4,668 (32) | 1,129 (29) | 3,100 (32) | 389 (34) | 989 (40) |
Histology: Non-small cell | 8,224 (56) | 2,066 (53) | 5,478 (57) | 822 (71) | 1,793 (73) |
Small cell | 1,828 (12) | 458 (12) | 1,218 (13) | 121 (10) | 303 (12) |
Missing | 4,683 (32) | 1,345 (35) | 2,868 (30) | 218 (19) | 378 (15) |
Smoking status prior to cancer diagnosis | |||||
Non-smoker | 1,907 (13) | 543 (14) | 1,188 (12) | 148 (13) | 339 (14) |
Ex-smoker | 5,214 (35) | 1,754 (45) | 3,111 (33) | 541 (47) | 852 (34) |
Current smoker | 5,961 (41) | 1,329 (34) | 4,138 (43) | 393 (34) | 1,042 (42) |
Missing | 1,653 (11) | 243 (6) | 1,127 (12) | 79 (7) | 241 (10) |
Alcohol consumption prior to diagnosis | |||||
Never | 2,311 (16) | 727 (19) | 1,385 (15) | 190 (16) | 342 (14) |
Ever | 9,707 (66) | 2,678 (69) | 6,337 (66) | 841 (72) | 1,712 (69) |
Missing | 2,717 (18) | 464 (12) | 1,842 (19) | 130 (11) | 420 (17) |
BMI (kg/m2) prior to diagnosis: mean (sd) | |||||
Underweight (<18.5) | 735 (5) | 175 (5) | 487 (5) | 38 (3) | 100 (4) |
Normal (18.5 to 25) | 5,325 (36) | 1,379 (36) | 3,543 (37) | 401 (35) | 943 (38) |
Overweight (25–30) | 3,916 (27) | 1,199 (31) | 2,444 (26) | 388 (33) | 695 (28) |
Obese (>30) | 1,702 (12) | 602 (16) | 1,002 (11) | 196 (17) | 287 (12) |
Missing | 3,057 (21) | 514 (13) | 2,088 (22) | 138 (12) | 449 (18) |
Deprivation fifth: 1st (least deprived) | 2,583 (18) | 650 (17) | 1,696 (18) | 206 (18) | 481 (19) |
2nd | 2,822 (19) | 754 (20) | 1,833 (19) | 236 (20) | 451 (18) |
3rd | 2,975 (20) | 778 (20) | 1,954 (20) | 232 (20) | 492 (20) |
4th | 3,235 (22) | 815 (21) | 2,102 (22) | 250 (22) | 556 (23) |
5th (most deprived) | 3,062 (21) | 859 (22) | 1,947 (20) | 233 (20) | 489 (20) |
Missing | 58 (0) | 13 (0) | 32 (0) | 4 (0) | 5 (0) |
Comorbidity prior to cancer diagnosis | |||||
Cerebrovascular disease | 1,.325 (9) | 746 (19) | 498 (5) | 147 (13) | 95 (4) |
Chronic pulmonary disease | 3,619 (25) | 1,054 (27) | 2,341 (25) | 307 (26) | 621 (25) |
Congestive heart disease | 954 (7) | 413 (11) | 483 (5) | 83 (7) | 76 (3) |
Diabetes | 1,552 (11) | 758 (20) | 698 (7) | 194 (17) | 141 (6) |
Myocardial infarction | 1,262 (9) | 866 (22) | 316 (3) | 223 (19) | 67 (3) |
Peptic ulcer disease | 1,087 (7) | 264 (7) | 745 (8) | 65 (6) | 182 (7) |
Peripheral vascular disease | 1,422 (10) | 780 (20) | 576 (6) | 200 (17) | 127 (5) |
Renal disease | 864 (6) | 441 (11) | 397 (4) | 97 (8) | 99 (4) |
Other medication use after diagnosis | |||||
Statin used | 4,801 (33) | 2,103 (54) | 1,193 (13) | 705 (61) | 410 (17) |
Beta-blocker used | 3,823 (26) | 1,143 (30) | 1,005 (11) | 416 (36) | 272 (11) |